Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

ANCHOR (OP-104) Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD And/or a Proteasome Inhibitor (PI): Phase 1 Update

Ludek Pour,Yvonne A. Efebera,Miquel Granell,Roman Hajek,Albert Oriol,Jacques Delaunay,Katell Le Du,Jean-Richard Eveillard,Lionel Karlin,Vladimir Maisnar,Joaquin Martinez-Lopez,Maria-Victoria Mateos,Maxim Norkin,Vincent Ribrag,Paul G. Richardson,Jan Straub,Catriona Byrne,Christian Jacques,Malin Sydvander,Enrique Ocio

Clinical lymphoma myeloma & leukemia/Clinical lymphoma, myeloma and leukemia（2019）

Cited 0|Views51
No score
Abstract
Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly cytotoxic payload into myeloma cells through peptidase activity. In phase 1/2 O-12-M1, melflufen plus dexamethasone had activity in RRMM with 31% ORR and 20.7 months median OS.
More
Translated text
Key words
melflufen,daratumumab,multiple myeloma,bortezomib,MM
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined